Avan J. Armaghani, MD, considers the evolution in therapies for metastatic breast cancer (mBC), from the bygone era of chemotherapy as the primary recourse to the enhanced contemporary scene, for which immunotherapy has opened new possibilities in strategic treatment.
Agents such as trastuzumab and pembrolizumab offer patients with mBC a range of second-line options that bring with them not just prospects of more immediate improvements in terms of safety and efficacy but also the anticipation of long-term benefits in the form of extended rates of survival.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Treatment of Metastatic Breast Cancer: A Multiplication of Options - Medscape - Aug 01, 2022.